Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: Thomson Reuters StreetEvents
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medivir AB supplemental New Drug Application has been submitted to the U.S. FDA for Simeprevir in combination with Sofosbuvir

Wednesday, 7 May 2014 06:50am EDT 

Medivir AB:Janssen has submitted supplemental New Drug Application (sNDA) to Food and Drug Association (FDA).For simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO(tm) in United States, in combination with nucleotide analogue NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc. 

Company Quote

1.0 +0.82%
30 Jul 2014